Patents by Inventor Guhan Balan
Guhan Balan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11433030Abstract: A dosage form with a first portion and a second portion. The first portion can be an immediate release portion and can comprise a pain reliever, which can be naproxen or naproxen sodium. The second portion can be an extended release portion and can comprise pseudoephedrine or a pharmaceutically acceptable salt thereof and/or dextromethorphan or a pharmaceutically acceptable salt thereof. The dosage form can optionally comprise a stabilizing agent. The dosage form can be adapted to maintain a therapeutically effective amount of pain reliever, pseudoephedrine, or a pharmaceutically acceptable salt thereof, and/or dextromethorphan, or a pharmaceutically acceptable salt thereof, for at least eight hours.Type: GrantFiled: December 16, 2019Date of Patent: September 6, 2022Assignee: The Procter & Gamble CompanyInventors: Mark Edward Stella, John Richard Entwisle, Baltej Ludher, Jonathan E. Clark, Daren K. Anness, Guhan Balan, Andrew Nicholas Carr
-
Publication number: 20200113841Abstract: A dosage form with a first portion and a second portion. The first portion can be an immediate release portion and can comprise a pain reliever, which can be naproxen or naproxen sodium. The second portion can be an extended release portion and can comprise pseudoephedrine or a pharmaceutically acceptable salt thereof and/or dextromethorphan or a pharmaceutically acceptable salt thereof. The dosage form can optionally comprise a stabilizing agent. The dosage form can be adapted to maintain a therapeutically effective amount of pain reliever, pseudoephedrine, or a pharmaceutically acceptable salt thereof, and/or dextromethorphan, or a pharmaceutically acceptable salt thereof, for at least eight hours.Type: ApplicationFiled: December 16, 2019Publication date: April 16, 2020Inventors: Mark Edward Stella, John Richard Entwisle, Baltej Ludher, Jonathan E. Clark, Daren K. Aness, Guhan Balan, Andrew Nicholas Carr
-
Patent number: 10576041Abstract: A dosage form with a first portion and a second portion. The first portion can be an immediate release portion and can comprise a pain reliever, which can be naproxen or naproxen sodium. The second portion can be an extended release portion and can comprise pseudoephedrine or a pharmaceutically acceptable salt thereof and/or dextromethorphan or a pharmaceutically acceptable salt thereof. The dosage form can optionally comprise a stabilizing agent. The dosage form can be adapted to maintain a therapeutically effective amount of pain reliever, pseudoephedrine, or a pharmaceutically acceptable salt thereof, and/or dextromethorphan, or a pharmaceutically acceptable salt thereof, for at least eight hours.Type: GrantFiled: September 25, 2017Date of Patent: March 3, 2020Assignee: The Procter & Gamble CompanyInventors: Mark Edward Stella, John Richard Entwisle, Baltej Ludher, Jonathan E. Clark, Daren K. Aness, Guhan Balan, Andrew Nicholas Carr
-
Patent number: 10517840Abstract: A method for temporarily relieving sinus congestion and pressure comprising administering to a human a dose of a multi-particle pulsatile oral dosage form with an immediate release form and a plurality of delayed release particles. The immediate release form contains about 10 mg phenylephrine hydrochloride. The delayed release form contains a core with coatings including a phenylephrine coating containing about 10 mg phenylephrine hydrochloride and a pH sensitive coating.Type: GrantFiled: March 7, 2019Date of Patent: December 31, 2019Assignee: The Procter & Gamble CompanyInventors: Richard John Dansereau, Daren Anness, Guhan Balan, David Ramsey
-
Patent number: 10376478Abstract: A multi-particle dosage form that can deliver phenylephrine in controlled pulsed doses. The dosage form can contain an immediate release form that can contain phenylephrine or a salt thereof and a plurality of delayed release particles with a coating that can contain phenylephrine or salt thereof and a pH sensitive coating.Type: GrantFiled: September 12, 2017Date of Patent: August 13, 2019Assignee: The Procter & Gamble CompanyInventors: Richard John Dansereau, Daren K. Anness, David L. Ramsey, Guhan Balan
-
Publication number: 20190201355Abstract: A method for temporarily relieving sinus congestion and pressure comprising administering to a human a dose of a multi-particle pulsatile oral dosage form with an immediate release form and a plurality of delayed release particles. The immediate release form contains about 10 mg phenylephrine hydrochloride. The delayed release form contains a core with coatings including a phenylephrine coating containing about 10 mg phenylephrine hydrochloride and a pH sensitive coating.Type: ApplicationFiled: March 7, 2019Publication date: July 4, 2019Inventors: Richard John Dansereau, Daren Anness, Guhan Balan, David Ramsey
-
Patent number: 10278930Abstract: A method for temporarily relieving sinus congestion and pressure comprising administering to a human a dose of a multi-particle pulsatile oral dosage form with an immediate release form and a plurality of delayed release particles. The immediate release form contains about 10 mg phenylephrine hydrochloride. The delayed release form contains a core with coatings including a phenylephrine coating containing about 10 mg phenylephrine hydrochloride and a pH sensitive coating.Type: GrantFiled: March 16, 2017Date of Patent: May 7, 2019Assignee: The Procter & Gamble CompanyInventors: Richard John Dansereau, Daren Anness, Guhan Balan, David Ramsey
-
Publication number: 20180263932Abstract: A method for temporarily relieving sinus congestion and pressure comprising administering to a human a dose of a multi-particle pulsatile oral dosage form with an immediate release form and a plurality of delayed release particles. The immediate release form contains about 10 mg phenylephrine hydrochloride. The delayed release form contains a core with coatings including a phenylephrine coating containing about 10 mg phenylephrine hydrochloride and a pH sensitive coating.Type: ApplicationFiled: March 16, 2017Publication date: September 20, 2018Inventors: Richard John Dansereau, Daren Anness, Guhan Balan, David Ramsey
-
Publication number: 20180085317Abstract: A dosage form with a first portion and a second portion. The first portion can be an immediate release portion and can comprise a pain reliever, which can be naproxen or naproxen sodium. The second portion can be an extended release portion and can comprise pseudoephedrine or a pharmaceutically acceptable salt thereof and/or dextromethorphan or a pharmaceutically acceptable salt thereof. The dosage form can optionally comprise a stabilizing agent. The dosage form can be adapted to maintain a therapeutically effective amount of pain reliever, pseudoephedrine, or a pharmaceutically acceptable salt thereof, and/or dextromethorphan, or a pharmaceutically acceptable salt thereof, for at least eight hours.Type: ApplicationFiled: September 25, 2017Publication date: March 29, 2018Inventors: Mark Edward Stella, John Richard Entwisle, Baltej Ludher, Jonathan E. Clark, Daren K. Aness, Guhan Balan, Andrew Nicholas Carr
-
Publication number: 20180000752Abstract: A multi-particle dosage form that can deliver phenylephrine in controlled pulsed doses. The dosage form can contain an immediate release form that can contain phenylephrine or a salt thereof and a plurality of delayed release particles with a coating that can contain phenylephrine or salt thereof and a pH sensitive coating.Type: ApplicationFiled: September 12, 2017Publication date: January 4, 2018Inventors: Richard John Dansereau, Daren K. Anness, David L. Ramsey, Guhan Balan
-
Patent number: 9795571Abstract: A multi-particle dosage form that can deliver phenylephrine in controlled pulsed doses. The dosage form can contain an immediate release form that can contain phenylephrine or a salt thereof and a plurality of delayed release particles with a coating that can contain phenylephrine or salt thereof and a pH sensitive coating.Type: GrantFiled: September 18, 2015Date of Patent: October 24, 2017Assignee: The Procter & Gamble CompanyInventors: Richard John Dansereau, Daren K. Anness, David L. Ramsey, Guhan Balan